Evidence map›Paper›PMID 34386936›Full record

Observational studyDrugs & aging2021

Anticholinergic Burden and Associated Healthcare Resource Utilization in Older Adults with Overactive Bladder.

Ashley Jaggi, Jameel Nazir, Francis Fatoye, Celine Quelen, Xinyi Tu, Mahmood Ali, Emad Siddiqui, Patrick J O Covernton, Margarita Landeira, Nurul Choudhury

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Drugs & aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Ashley JaggiManchester Metropolitan University, Manchester, M15 6GX, UK. ashleyjaggi@hotmail.com.
Jameel NazirAstellas Pharma Europe Ltd, Addlestone, UK.
Francis FatoyeManchester Metropolitan University, Manchester, M15 6GX, UK.
Celine QuelenCreativ-Ceutical, London, UK.
Xinyi TuCreativ-Ceutical, London, UK.
Mahmood AliManchester Metropolitan University, Manchester, M15 6GX, UK.
Emad SiddiquiAstellas Pharma Europe Ltd, Addlestone, UK.
Patrick J O CoverntonAstellas Pharma Europe Ltd, Addlestone, UK.
Margarita LandeiraAstellas Pharma Europe Ltd, Addlestone, UK.
Nurul ChoudhuryAstellas Pharma Europe Ltd, Addlestone, UK.
Astellas Pharma (United Kingdom) · GBManchester Metropolitan University · GBAstraZeneca (Sweden) · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBladder anticholinergics are the most widely used drugs to treat overactive bladder (OAB) but can contribute to cumulative anticholinergic burden, which may be associated with adverse outcomes.

objectiveThis study aimed to evaluate the association between cumulative anticholinergic burden and healthcare resource utilization (HRU) and costs in older adults with OAB. MATERIALS AND

methodsThis was a retrospective, observational study that used data from the UK Clinical Practice Research Datalink (CPRD) GOLD database. Participants were aged ≥ 65 years with ≥ 3 years of continuous enrolment before and ≥ 2 years after the index date (date of OAB diagnosis or first prescription for any OAB drug between 1 April 2007 and 31 December 2015). The primary endpoint was the association between cumulative anticholinergic burden (assessed using the Anticholinergic Cognitive Burden [ACB] scale during the 3-year pre-index period) and HRU (GP consultations, specialist referrals, urological tests, hospital admissions) over the 2-year post-index period.

resultsData from 23,561 adults were included in the analysis. Mean (SD) ACB scores in the pre- and post-index periods were 1.0 (1.1) and 2.4 (1.7), respectively; urological drugs contributed most (58.8%) to the latter. For the primary endpoint, higher pre-index ACB scores were associated with higher post-index HRU and costs. Mean (SD) ACB scores in the post-index period were 1.2 (1.3) and 2.5 (1.7) in those treated with mirabegron (beta-3 agonist) or bladder anticholinergics, respectively. LIMITATIONS: The generalizability of the results outside the UK is unclear.

conclusionsIn older adults with OAB, higher anticholinergic burden before initiating OAB drugs is associated with higher HRU and costs. When making treatment decisions in older adults, consideration should be given to assessing the existing anticholinergic burden and using OAB treatments that do not add to this burden.

Indexed as

Urinary Bladder, OveractiveAgedCholinergic AntagonistsHumansPatient Acceptance of Health CareRetrospective StudiesCholinergic Antagonists

Identifiers

PMID34386936
PMCPMC8484210
OpenAlexW3190173209

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.